Suche
Mein Konto
Modified CEUS criteria using perfluorobutane may help diagnose high-risk hepatocellular carcinoma
According to an accepted manuscript published in the American Journal of Roentgenology (AJR) by ARRS, the diagnostic performance of LR-5 for the diagnosis of hepatocellular carcinoma (HCC) was not significantly different between modified contrast-enhanced ultrasound (CEUS) with perfluorobutane and CT/MRI LI -RADS version 2018. The results support the use of modified CEUS criteria using perfluorobutane for the diagnosis of HCC in high-risk patients.” Jianhua Zhou, MD, PhD, State Key Laboratory of Oncology, Sun Yat-Sen University Cancer Center in Guangzhou, South China In this manuscript accepted by AJR, 171 patients (140 men, 31 women; mean age 54 years) with high risk of HCC and a pathological...
Modified CEUS criteria using perfluorobutane may help diagnose high-risk hepatocellular carcinoma
According to an accepted manuscript published in the American Journal of Roentgenology (AJR) by ARRS, the diagnostic performance of LR-5 for the diagnosis of hepatocellular carcinoma (HCC) was not significantly different between modified contrast-enhanced ultrasound (CEUS) with perfluorobutane and CT/MRI LI -RADS version 2018.
The results support the use of modified CEUS criteria using perfluorobutane to diagnose HCC in high-risk patients.”
Jianhua Zhou, MD, PhD, State Key Laboratory of Oncology, Sun Yat-Sen University Cancer Center in Guangzhou, southern China
In this AJR-accepted manuscript, 171 patients (140 men, 31 women; mean age 54 years) with high risk of HCC and a pathologically confirmed liver observation were examined by CEUS using perfluorobutane and contrast-enhanced CT or MRI between March 2020 and May 2021. A matching algorithm was used to match 2 patients with To select HCC for any patient with a non-HCC lesion. Two readers evaluated observations using proposed changes to CEUS LI-RADS version 2017 that classify certain observations as LR-5 rather than LR-4 or LR-M based on the presence of a defect following perfluorobutane administration.
Ultimately, modified CEUS criteria using perfluorobutane and CT/MRI LI-RADS v2018 showed no significant difference in sensitivity (92.1% vs. 89.5%), specificity (87.9% vs. 84.2%), or accuracy (90.6% vs. 87.7%). of LR-5 for HCC. All observations assigned LR-4 (n=5) or LR-M (n=6) by CT/MRI LI-RADS v2018 but LR-5 by modified CEUS were HCC.
“Modified CEUS criteria performed similarly to CT/MRI LI-RADS v2018 and additional HCCs in a subset of observations assigned LR-4 or LR-M from CT/MRI LIRADS v2018,” reiterated the authors of this AJR-accepted manuscript.
Source:
Reference:
Li, L., et al. (2022) Intra-individual comparison of contrast-enhanced ultrasound with perfluorobutane with modified criteria versus CT/MRI LI-RADS version 2018 for the diagnosis of HCC in high-risk patients. American Journal of Radiology. doi.org/10.2214/AJR.22.28420.
.